News | March 18, 2019

PDS Biotechnology Completes Merger with Edge Therapeutics Shares of Combined Company to Commence Trading on Nasdaq Capital Market under New Symbol “PDSB” on March 18, 2019 PRINCETON, N.J., March 18, 2019 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (“PDS...

News | February 4, 2019

Neurana Pharmaceuticals Announces First Patient Enrolled in the STAR Study Neurana Pharmaceuticals Announces First Patient Enrolled in the “STAR Study,” a Phase 2 Dose Ranging Study of Tolperisone in Acute Muscle Spasms of the Back SAN DIEGO, February 4th, 2019...

News | March 2, 2019

PRINCIPIA BIOPHARMA ANNOUNCES POSITIVE DATA FROM PHASE 2 PEMPHIGUS VULGARIS TRIAL AT 2019 AMERICAN ACADEMY OF DERMATOLOGY ANNUAL MEETING IN LATE-BREAKING PRESENTATION Reached primary endpoint of Control of Disease Activity at four weeks in 54 percent of patients on...

News | February 7, 2019

HARPOON THERAPEUTICS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Harpoon Therapeutics, Inc. (“Harpoon”), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today the...

News | January 2, 2019

HARPOON THERAPEUTICS ANNOUNCES PRELIMINARY SAFETY AND PHARMACOLOGY DATA FROM ITS HPN424 PHASE 1 TRIAL IN PROSTATE CANCER Initial data shows HPN424 serum exposure supports weekly dosing Changes in blood-derived tumor cell and serum biomarkers consistent with T cell...
Donec Aliquam Curabitur leo. Praesent risus justo venenatis